Gary Pace

Gary William Pace founded Transcend Therapeutics, Inc. in 1992 and Sova Pharmaceuticals, Inc. in 2010, where he worked as Director in 2010.
Dr. Pace also currently works at View Point Medical, Inc., as Executive Chairman, Protiveris, Inc., as Director, NeuroMedix, Inc., as Director, Cardiff Oncology, Inc., as Independent Director from 2020, Sacron Innovations Pty Ltd., as Director, Upstream Medical Technologies Ltd., as Director, Immunicom, Inc., as Director, Curtana Pharmaceuticals, Inc., as Director, The University of Queensland, as Professor, and Pacific Channel Ltd., as Partner & Investment Committee Chair.
Dr. Pace also formerly worked at Waratah Pharmaceuticals, Inc., as Chairman & Chief Executive Officer from 2000 to 2002, SkyePharma Canada, Inc., as President & Chief Executive Officer from 1995 to 2001, Hunter Immunology Pty Ltd., as Vice Chairman, ResMed, Inc., as Independent Director from 1994 to 2018, Imunon, Inc., as Director from 2002 to 2010, Transition Therapeutics, Inc., as Independent Director from 2002 to 2018, Percheron Therapeutics Ltd., as Independent Non-Executive Director from 2015 to 2022, Peplin Ltd., as Director in 2009, Guardian Medical Solutions Ltd., as Independent Non-Executive Director from 2001 to 2013, Peplin, Inc., as Director from 2004 to 2009, Invitrocue Ltd., as Independent Non-Executive Director from 2018 to 2019, Breathe Easy Ltd., as Director, Simavita Ltd., as Independent Non-Executive Director from 2016 to 2021, Footfalls & Heartbeats (UK) Ltd., as Director from 2013 to 2015, AVACEN, Inc., as Director, Engender Technologies Ltd., as Director, Pacira Biosciences, Inc., as Independent Director from 2008 to 2024, and Clintec International, Inc. (Illinois), as Senior Vice President-Research & Development from 1989 to 1993.
Dr. Pace received his doctorate degree in 1975 from Massachusetts Institute of Technology and undergraduate degree in 1974 from The University of New South Wales.